Please check out our latest topic on Hepatitis C and its treatment summary using Sovaldi (Sofosbuvir), Harvoni (Sofosbuvir + Ledipasvir) and Daclatasvir (Daklinza) with more than 90% cure rate on all genotypes.
Hepatitis C is an infection of the liver by the Hepatitis C virus (HCV). For reasons that are currently unknown, approximately 20% of people are able to self-clear the HCV during the first 6 months of infection without receiving any treatments. Unfortunately, for the rest, the HCV stays in the liver and a chronic life-long infection develops. Over time, chronic Hepatitis C continuously causes damages to the liver leading to serious health problems including liver diseases, cirrhosis (severe scarring/hardening of the liver), liver failure, and even liver cancer. It is estimated 130–150 million people globally have chronic hepatitis C infection. A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer and approximately 500,000 people die each year from hepatitis C-related liver diseases. In October 2013, US FDA unanimously voted to recommend approving Sovaldi (Sofosbuvir) by Gilead Sciences Inc. for use in patients with Hepatitis C. Sofosbuvir is the first all-oral option for patients with HCV. More information on the topic: https://www.liferelayhealthcare.com/hepatitis-c/
All the Hep C drugs can be purchased at Life Relay Health Care Solutions, your trusted Canadian pharmacy service. Please feel free to consult our pharmacists at toll free number 1-888-488-9965 to buy Sovaldi, buy Harvoni and buy Daclatasvir.